

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person* <u>Howton David T</u>  (Last) (First) (Middle) 215 FIRST STREET, SUITE 415  (Street) CAMBRIDGE MA 02142  (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Sarepta Therapeutics, Inc. [ SRPT ]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director _____ 10% Owner _____ Officer (give title below) _____ Other (specify below) _____ <b>EVP, General Counsel</b>
	3. Date of Earliest Transaction (Month/Day/Year) 06/22/2020	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	06/22/2020		M <sup>(1)</sup>		1,280	A	\$13.71	33,151	D	
Common Stock	06/22/2020		M <sup>(1)</sup>		1,858	A	\$13.71	35,009	D	
Common Stock	06/22/2020		M <sup>(1)</sup>		56,984	A	\$23.85	91,993	D	
Common Stock	06/22/2020		M <sup>(1)</sup>		45,000	A	\$29.03	136,993	D	
Common Stock	06/22/2020		S <sup>(1)</sup>		6,009	D	\$168.61 <sup>(2)</sup>	130,984	D	
Common Stock	06/22/2020		S <sup>(1)</sup>		8,086	D	\$169.56 <sup>(3)</sup>	122,898	D	
Common Stock	06/22/2020		S <sup>(1)</sup>		35,757	D	\$170.59 <sup>(4)</sup>	87,141	D	
Common Stock	06/22/2020		S <sup>(1)</sup>		55,270	D	\$171.5 <sup>(5)</sup>	31,871	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Stock option (right to buy)	\$13.71	06/22/2020		M <sup>(1)</sup>			1,280	02/28/2017	02/28/2026	Common Stock	1,280	\$0.00	0	D	
Stock option (right to buy)	\$13.71	06/22/2020		M <sup>(1)</sup>			1,858	02/28/2017	02/28/2026	Common Stock	1,858	\$0.00	0	D	
Stock option (right to buy)	\$23.85	06/22/2020		M <sup>(1)</sup>			56,984	11/05/2013	11/05/2022	Common Stock	56,984	\$0.00	0	D	
Stock option (right to buy)	\$29.03	06/22/2020		M <sup>(1)</sup>			45,000	02/28/2015	02/28/2024	Common Stock	45,000	\$0.00	7,708	D	

Explanation of Responses:

- This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction.
- The shares were sold in transactions at prices ranging from \$168.04 to \$169.0399, inclusive. The reporting person undertakes to provide to Sarepta Therapeutics, Inc., any security holder of Sarepta Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
- The shares were sold in transactions at prices ranging from \$169.09 to \$170.0899, inclusive. The reporting person undertakes to provide to Sarepta Therapeutics, Inc., any security holder of Sarepta Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
- The shares were sold in transactions at prices ranging from \$170.09 to \$171.0899, inclusive. The reporting person undertakes to provide to Sarepta Therapeutics, Inc., any security holder of Sarepta Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
- The shares were sold in transactions at prices ranging from \$171.09 to \$172.0899, inclusive. The reporting person undertakes to provide to Sarepta Therapeutics, Inc., any security holder of Sarepta Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

Remarks:

/s/ David Tyrone Howton 06/22/2020  
 \*\* Signature of Reporting Person Date

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**